{"id":"W2093786954","doi":"10.1097/qad.0000000000000519","title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials","year":2014,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Medicine; Emtricitabine; Darunavir; Raltegravir; Internal medicine; Efavirenz; Ritonavir; Lamivudine; Confidence interval; Integrase inhibitor; Clinical endpoint; Randomized controlled trial; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Hepatitis B virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03231781,0.00218644,0.005253299,0.001087102,0.001082115,0.002891834,0.001287063,0.003082936,0.003015249],"category_scores_gemma":[0.03510616,0.0009853588,0.01317731,0.001444508,0.001814796,0.001628585,0.001534086,0.003060251,0.0003286958],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001953391,"about_ca_system_score_gemma":0.003178828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00138174,"about_ca_topic_score_gemma":0.00391326,"domain_scores_codex":[0.9729614,0.01911733,0.003874589,0.001734902,0.001274556,0.001037144],"domain_scores_gemma":[0.9770952,0.01199168,0.005927862,0.002090446,0.001531838,0.001362957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9465169,0.001158706,0.006718636,0.002955051,0.02587094,0.00005646296,0.0002727623,0.0004654056,0.001545579,0.0002151678,0.0004044727,0.0138199],"study_design_scores_gemma":[0.9272497,0.02831143,0.01386519,0.0006689625,0.02591319,0.00008541611,0.0001590145,0.0007283755,0.000833075,0.0007236231,0.001398494,0.00006353352],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9278449,0.04867947,0.003324184,0.00127618,0.0004574097,0.0134266,0.002217521,0.0001702303,0.002603547],"genre_scores_gemma":[0.9826047,0.004381964,0.002392136,0.0007383027,0.0001159437,0.008252963,0.001009282,0.00002481576,0.0004799213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03231781,"threshold_uncertainty_score":0.170915,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03121098539188963,"score_gpt":0.3000794909422271,"score_spread":0.2688685055503375,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}